Guiling Zhao

发表

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

K. Scearce-Levie, A. Beresford, A. Medhurst, 2012, Journal of medicinal chemistry.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Adam R. Johnson, N. C. Ray, Rohan V Mendonca, 2019, Bioorganic & medicinal chemistry letters.

Strategies to Increase the Production of Biosynthetic Riboflavin

Xingzhen Lao, Heng Zheng, Guiling Zhao, 2021, Molecular Biotechnology.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Karl H. Clodfelter, Zhongguo Wang, Mark Zak, 2013, Journal of medicinal chemistry.

Applications of machine‐learning methods for the discovery of NDM‐1 inhibitors

Heng Zheng, Xingzhen Lao, Fanyi Dong, 2020, Chemical biology & drug design.

Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.

Jason Drummond, Xingrong Liu, Yichin Liu, 2012, Journal of medicinal chemistry.

The Prospect of Bioactive Peptide Research: A Review on Databases and Tools

Heng Zheng, Fanyi Dong, Guiling Zhao, 2020, Current Bioinformatics.

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.

S. Steinbacher, BinQing Wei, C. Eigenbrot, 2017, Journal of medicinal chemistry.

Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.

Yang Xiao, Lei Zhang, Karl H. Clodfelter, 2013, Bioorganic & medicinal chemistry letters.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.

N. Skelton, D. Sampath, K. Bair, 2016, Journal of medicinal chemistry.

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.

Karl H. Clodfelter, N. Skelton, D. Sampath, 2015, Bioorganic & medicinal chemistry letters.

Deep Learning in the Study of Protein-Related Interactions: Review.

Jiaxing Chen, Heng Zheng, Xingzhen Lao, 2020, Protein and peptide letters.

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Journal of medicinal chemistry.

Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2014, Bioorganic & medicinal chemistry letters.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.